Cardiac Biotech Solutions, Inc. (OTCID: CBSC) is a medical device company focused on non-invasive ambulatory cardiac monitoring, supported by cloud-based software and mobile applications.

The Company’s flagship product, MyCardia AT, is designed to assist physicians in the detection and evaluation of cardiac arrhythmias during extended monitoring periods.

Key Regulatory & Commercial Milestones

• United States: The Company has received clearance from the U.S. Food and Drug Administration for its MyCardia AT cardiac event monitoring device, enabling commercial distribution in the U.S.
• Canada: The Company has received a Medical Device License (MDL) from Health Canada for MyCardia AT (marketed in Canada as CardioHolter AT), permitting import and commercialization.
• Commercialization: The Company has announced initial distributor purchase orders and commercial agreements in Canada and international markets.
• International Expansion: The Company is advancing regulatory and distribution initiatives in additional international markets, including China, in collaboration with manufacturing and distribution partners.